Director, Global Medical Oncology, Emerging Assets at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Advanced scientific degree (MD, PhD, PharmD) with oncology specialization preferred
Minimum 5-7 years of experience in medical affairs or clinical development within the biopharmaceutical industry
Proven leadership in global medical strategy and cross-functional team management
Strong understanding of oncology therapeutic landscape, particularly thoracic cancers
Excellent communication, stakeholder engagement, and strategic planning skills

Responsibilities

Drive the development and execution of the global medical strategy for Iza-bren, ensuring alignment with clinical development, commercial, and access teams
Serve as an advisor and collaborator to the MPL to support the Global Product Team (GPT) and cross-functional launch teams
Translate clinical development insights into medical plans that support launch readiness and lifecycle management
Engage with key external stakeholders including thought leaders, investigators, and advocacy groups to gather insights and foster scientific exchange
Represent BMS at global oncology congresses and forums, elevating the visibility of Iza-bren and its clinical value
Partner with R&D to influence trial design, endpoints, and data generation strategies for Iza-bren
Collaborate with Commercial, Market Access, and HEOR to integrate medical perspectives into brand strategy and patient journey mapping
Work closely with Medical Communications teams to ensure scientific alignment and impactful dissemination of data
Lead the medical planning process for Iza-bren, including budgeting, resource forecasting, and performance tracking
Provide medical review and strategic input for content development, ensuring consistency with asset strategy
Facilitate matrix meetings and ensure effective follow-up on decisions, risks, and action items
Identify opportunities for innovation in medical execution, including digital engagement and real-world evidence generation
Contribute to broader Oncology initiatives such as Project Converge and strategic planning across Thoracic and H&N tumors
Support business development evaluations and alliance partnerships relevant to Iza-bren

Skills

Oncology

Antibody Drug Conjugates

ADC

EGFR

HER3

Bispecific Antibodies

Medical Strategy

Clinical Development

Cross-Functional Leadership

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free